Ashland Inc. reported second-quarter fiscal 2025 sales of $479 million, a 17% decrease year-over-year, significantly impacted by portfolio optimization initiatives that reduced sales by $67 million. Net income was $31 million, down from $120 million in the prior year, with diluted earnings per share of $0.63. Adjusted EBITDA decreased by 14% to $108 million, with portfolio optimization accounting for a $13 million reduction.
The company experienced a mixed demand environment and lower-than-expected sales volumes, particularly in Personal Care and Specialty Additives, while Intermediates faced persistent pricing pressure. Cash flows from operating activities were $9 million, a decrease from $54 million in the prior-year quarter. Ashland repurchased 1.5 million shares during the quarter, with $520 million remaining under authorization.
Ashland revised its full-year fiscal 2025 outlook, now projecting sales in the range of $1.825 billion to $1.9 billion and Adjusted EBITDA between $400 million and $420 million. This revision reflects a slower-than-expected market recovery and continued macroeconomic headwinds, particularly subdued demand in Europe and competitive intensity in certain markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.